Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Sell
22
ATRA Quote, Financials, Valuation and Earnings
Last price:
$4.49
Seasonality move
:
-12.66%
Day range:
$4.45 - $4.68
52-week range:
$4.20 - $19.15
Dividend yield:
0%
P/E ratio:
2.03x
P/S ratio:
0.35x
P/B ratio:
--
Volume:
29.9K
Avg. volume:
520.1K
1-year change:
-48.97%
Market cap:
$32.1M
Revenue:
$128.9M
EPS (TTM):
$2.19
Analysts' Opinion
-
Consensus RatingAtara Biotherapeutics, Inc. has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 2 Buy ratings, 2 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $8.67, Atara Biotherapeutics, Inc. has an estimated upside of 94.76% from its current price of $4.45.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $4.00 representing 100% downside risk from its current price of $4.45.
Fair Value
-
According to the consensus of 5 analysts, Atara Biotherapeutics, Inc. has 94.76% upside to fair value with a price target of $8.67 per share.
ATRA vs. S&P 500
-
Over the past 5 trading days, Atara Biotherapeutics, Inc. has underperformed the S&P 500 by -7.48% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Atara Biotherapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Atara Biotherapeutics, Inc. revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Atara Biotherapeutics, Inc. reported revenues of $3.5M.
Earnings Growth
-
Atara Biotherapeutics, Inc. has grown year-over-year earnings for 5 quarters straight. In the most recent quarter Atara Biotherapeutics, Inc. reported earnings per share of -$0.32.
Enterprise value:
77M
EV / Invested capital:
--
Price / LTM sales:
0.35x
EV / EBIT:
2.05x
EV / Revenue:
0.51x
PEG ratio (5yr expected):
-0.16x
EV / Free cash flow:
-1.10x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
1.92x
Gross Profit (TTM):
$124M
Return On Assets:
30.72%
Net Income Margin (TTM):
15.4%
Return On Equity:
-2818.48%
Return On Invested Capital:
212.25%
Operating Margin:
-102.72%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $4.5M | $100.4M | $151.9M | $40.2M | $3.5M | |
| Gross Profit | -$13.5M | $83.1M | $124M | $32.6M | $3.3M | |
| Operating Income | -$291.5M | -$119.4M | $37.6M | -$21.8M | -$3.5M | |
| EBITDA | -$277.9M | -$114.2M | $40.2M | -$20.5M | -$3.5M | |
| Diluted EPS | -$18.52 | -$25.66 | $2.19 | -$2.93 | -$0.32 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $369.5M | $283M | $118.7M | $91.9M | $18.4M | |
| Total Assets | $449.9M | $368.3M | $188.8M | $142.7M | $30.2M | |
| Current Liabilities | $86.2M | $72.2M | $79.1M | $156M | $18.1M | |
| Total Liabilities | $139.8M | $181.2M | $239.6M | $233.2M | $66.8M | |
| Total Equity | $310.1M | $187.1M | -$50.8M | -$90.5M | -$36.6M | |
| Total Debt | $24.6M | $65.7M | $49.4M | $74.4M | $56.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$199.5M | -$94.7M | -$69.7M | -$4M | -$9.8M | |
| Cash From Investing | $165.1M | $15.2M | $13.1M | -$16.7M | -$2.4M | |
| Cash From Financing | $32.8M | $61.1M | $15.8M | $35.8M | $1M | |
| Free Cash Flow | -$200.7M | -$94.9M | -$69.8M | -$4M | -$9.8M | |
ATRA
Sector
Market Cap
$32.1M
$24M
Price % of 52-Week High
23.24%
48.29%
Dividend Yield
0%
0%
Shareholder Yield
-9.79%
-1.62%
1-Year Price Total Return
-48.97%
-22.92%
Beta (5-Year)
-0.433
0.500
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$4.69
200-day SMA
Sell
Level
$11.16
Bollinger Bands (100)
Sell
Level
7.95 - 17.07
Chaikin Money Flow
Sell
Level
-7.8M
20-day SMA
Sell
Level
$4.92
Relative Strength Index (RSI14)
Sell
Level
28.64
ADX Line
Sell
Level
37.29
Williams %R
Buy
Level
-93.6803
50-day SMA
Sell
Level
$10.97
MACD (12, 26)
Sell
Level
-1.67
25-day Aroon Oscillator
Sell
Level
-28
On Balance Volume
Sell
Level
-4.4M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-28.0923)
Sell
CA Score
(Annual)
Level (-8.2495)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (14.3769)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (9)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.
Stock Forecast FAQ
In the current month, ATRA has received 2 Buy ratings 2 Hold ratings, and 1 Sell ratings. The ATRA average analyst price target in the past 3 months is $8.67.
-
Where Will Atara Biotherapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Atara Biotherapeutics, Inc. share price will rise to $8.67 per share over the next 12 months.
-
What Do Analysts Say About Atara Biotherapeutics, Inc.?
Analysts are divided on their view about Atara Biotherapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Atara Biotherapeutics, Inc. is a Sell and believe this share price will drop from its current level to $4.00.
-
What Is Atara Biotherapeutics, Inc.'s Price Target?
The price target for Atara Biotherapeutics, Inc. over the next 1-year time period is forecast to be $8.67 according to 5 Wall Street analysts, 2 of them rate the stock a Buy, 1 rates the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is ATRA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Atara Biotherapeutics, Inc. is a Leans Bullish. 2 of 5 analysts rate the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of ATRA?
You can purchase shares of Atara Biotherapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Atara Biotherapeutics, Inc. shares.
-
What Is The Atara Biotherapeutics, Inc. Share Price Today?
Atara Biotherapeutics, Inc. was last trading at $4.49 per share. This represents the most recent stock quote for Atara Biotherapeutics, Inc.. Yesterday, Atara Biotherapeutics, Inc. closed at $4.45 per share.
-
How To Buy Atara Biotherapeutics, Inc. Stock Online?
In order to purchase Atara Biotherapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get ATRA Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ATRA
Sector
P/E ratio
2.03x
23.44x
PEG ratio
-0.16x
-0.01x
P/B ratio
--
1.73x
Price / LTM sales
0.35x
1.51x
Growth Metrics
ATRA
Sector
Revenue growth
-91.41%
3.31%
Earnings growth
89.19%
10.7%
Revenue (5-year growth)
--
6.28%
Earnings forecast
-$0.03
-$0.19
Profitability
ATRA
Sector
Profitability FY 2024
$107.9M
$2.6M
Return on invested capital
212.25%
-33.62%
Return on assets
30.72%
-29.74%
Return on equity
-2818.48%
-39.33%
Earnings Date
Last Earnings Date
Nov
12
Next Earnings Date
Mar
5
Estimated Next Earnings Date
Feb
11
Balance Sheet
ATRA
Sector
Total cash
$13.7M
$25M
Short term investments
$17.5M
$23.9M
Total assets
$109.1M
$71.9M
Long term debt
$56.7M
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Is Sandisk The Next Big Memory Stock?
Computer memory manufacturer Sandisk (NASDAQ:SNDK) has quietly been one of…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
77
CPS alert for Feb 14
Cooper-Standard Holdings, Inc. [CPS] is up 32.06% over the past day.
Buy
58
TPH alert for Feb 14
Tri Pointe Homes, Inc. [TPH] is up 26.83% over the past day.
Sell
20
IRON alert for Feb 14
Disc Medicine, Inc. [IRON] is down 21.88% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
